IQVIA Holdings Inc. $IQV Shares Sold by Glenmede Investment Management LP

Glenmede Investment Management LP reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 202,711 shares of the medical research company’s stock after selling 19,677 shares during the quarter. Glenmede Investment Management LP owned 0.12% of IQVIA worth $38,503,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IQV. Brighton Jones LLC grew its holdings in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its position in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in IQVIA in the second quarter worth about $514,000. Penserra Capital Management LLC increased its holdings in IQVIA by 10.3% in the second quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after buying an additional 90 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in IQVIA by 6.8% in the second quarter. ProShare Advisors LLC now owns 34,139 shares of the medical research company’s stock valued at $5,380,000 after buying an additional 2,170 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Morgan Stanley set a $240.00 target price on IQVIA in a research report on Wednesday, February 11th. BMO Capital Markets set a $250.00 price target on IQVIA in a research report on Friday, February 6th. Evercore reaffirmed an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a report on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Finally, Truist Financial dropped their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $229.13.

IQVIA Trading Up 1.1%

NYSE:IQV opened at $164.78 on Friday. The firm has a market capitalization of $27.96 billion, a P/E ratio of 20.96, a P/E/G ratio of 1.57 and a beta of 1.39. The business has a 50 day simple moving average of $201.58 and a 200 day simple moving average of $206.67. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.